Journal article
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer
C Murphy, N Turner, HL Wong, M Sinnathamby, J Tie, B Lee, J Desai, I Skinner, M Christie, R Hutchinson, S Lunke, P Waring, P Gibbs, B Tran
Internal Medicine Journal | WILEY | Published : 2017
DOI: 10.1111/imj.13312
Abstract
Background/Aim: Data suggest aspirin improves survival in colorectal cancer (CRC) harbouring PIK3CA mutations. The impact of aspirin is thought predominantly to be through an anti-inflammatory effect. The aim of this study is to explore the effect of aspirin use on survival in a real-world cohort of stage 2 colon cancer (CC) patients. Methods: A prospective CRC database identified patients diagnosed with stage 2 CC between 2000 and 2011. PIK3CA mutation status was determined by next generation sequencing. Neutrophil-lymphocyte ratio greater than 5 at diagnosis represented systemic inflammation. Chart review was used to record regular aspirin use at diagnosis. Clinico-pathological features an..
View full abstractGrants
Funding Acknowledgements
This project was funded by Western Health Oncology Research Unit.